Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Date:11/3/2009

n 18-month period, sell up to $60 million newly issued registered common stock to Azimuth Opportunity Ltd. at a pre-negotiated discount to market price. The Company will determine, at its sole discretion, the timing and amount of any sales of its common stock, subject to certain conditions. The Company is not obligated to utilize any of the $60 million facility and remains free to enter into other financing transactions.

Third Quarter 2009 Unaudited Financial Results

The Company reported a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009, compared with a net loss of $12.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $12.4 million) for the quarter ended September 30, 2008. The Company reported a net loss of $32.5 million ($0.95 diluted loss per share on a loss applicable to common shares of $32.9 million) for the nine months ended September 30, 2009, compared with a net loss of $34.6 million ($1.01 diluted loss per share on a loss applicable to common shares of $35.0 million) for the same period in 2008.

Total operating expenses for the quarter ended September 30, 2009, were $9.2 million compared with $12.4 million for the quarter ended September 30, 2008, and were $30.5 million for the nine months ended September 30, 2009, compared with $35.8 million for the same period in 2008. Total operating expenses for the nine months ended September 30, 2009, include a charge of $1.1 million for the restructuring and related asset impairment resulting from the Company's implementation of a strategic restructuring plan to discontinue its in-house preclinical research operations and reduce its workforce by approximately 12 percent effective March 31, 2009.

Research and development expenses were $5.4 million for the quarter ended September 30, 2009, compared with $9.0 million for
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure BioSciences, ... worldwide leader in the development and sale of ... sciences research market, today announced that Professor ... novel, accurate, highly reproducible, and robust method to ... high-throughput protein analysis on small needle biopsy samples ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... 24 The Pittsburgh Life Sciences,Greenhouse (PLSG), ... industry on a fast track for growth, ... Innovention Technologies, LLC, a developmental-stage,medical device company, ... a,highly-maneuverable surgical probe that will alleviate the ...
... The Interstate,Alliance for Stem Cell Research should adopt a ... the Foundation for Taxpayer and,Consumer Rights (FTCR) said today., ... state,stem cell programs, is meeting today and Thursday at ... still in its early stages, it is critical to ...
... Calif., Oct. 24 Immunosyn,Corporation,s (OTC Bulletin Board: ... brokers and financial institutions at the Financial,Services Exchange ... in Phoenix, AZ on Thursday, October 25, 2007. ... and,distribution rights to SF-1019 from its largest shareholder, ...
Cached Biology Technology:The PLSG Invests $115,000 in Innovention Technologies, LLC 2Consumers Call On Interstate Stem Cell Group To Endorse Open Meetings 2Immunosyn Corporation to Present at FSX 2
(Date:10/30/2014)... news release is available in German . ... as individuals prompt our fellow humans to behave socially? ... social dilemmas in game theory. Previous studies assumed that ... groups. Nonetheless, scientists from the Max Planck Institute for ... can exert an influence on the cooperative behaviour of ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/30/2014)... Heidelberg, 30 October 2014 Biological membranes are mainly ... of adsorption of solution ions onto lipid membranes ... a new study provides a quantitative description of ... ions. Joanna Kotyńska and Zbigniew Figaszewski from the ... a study describing these findings, just published in ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2
... result of natural processes that exploited early Earth,s raw ... to minerals for such essential tasks as the synthesis ... metabolic energy. But this assumes that the mineral species ... they were during Earth,s first 550 million yearsthe Hadean ...
... size increases, so do portion size and the amount of ... how susceptible people are to this plate-size bias? New research ... and introverted children respond differently to environmental cues, such as ... examined the breakfast behaviors of kids, ages 6 to 10, ...
... discovery may help explain the surprisingly strong connections between ... Sleep loss increases the risk of Alzheimer,s ... signs of this devastating disorder. Scientists at Washington ... University of Pennsylvania have shown that brain cell damage ...
Cached Biology News:Ancient minerals: Which gave rise to life? 2Extrovert and introvert children are not equally influenced by plate size 2Broken cellular 'clock' linked to brain damage 2Broken cellular 'clock' linked to brain damage 3
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
... Leu-CMK FLISP Assay with FAM-Labeled Substrate ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: